AbbVie Inc (WBO:ABBV) Stock News, Headlines & Updates
AbbVie Inc Stock News from GuruFocus
- 1
- 2
Jul 02, 2024
AbbVie to Host Second-Quarter 2024 Earnings Conference Call
PRNewswire • 8:00am
Jul 01, 2024
Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
PRNewswire • 8:00am
Jun 28, 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
PRNewswire • 2:00am
Jun 27, 2024
AbbVie Acquires Celsius Therapeutics
PRNewswire • 9:00am
Introducing All? Payment Plans, Powered by Cherry
PRNewswire • 8:00am
U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
PRNewswire • 7:00pm
Jun 25, 2024
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
PRNewswire • 8:00am
The Art of Valuation: Discovering AbbVie Inc's Intrinsic Value
GuruFocus Research • 6:00am
Jun 21, 2024
AbbVie Declares Quarterly Dividend
PRNewswire • 8:00am
Jun 20, 2024
AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors
PRNewswire • 8:00am
Jun 18, 2024
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
PRNewswire • 6:00pm
Jun 14, 2024
AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
PRNewswire • 4:00pm
Jun 13, 2024
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
PRNewswire • 7:00am
Jun 11, 2024
BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients
PRNewswire • 8:00am
The Art of Valuation: Discovering AbbVie Inc's Intrinsic Value
GuruFocus Research • 6:00am
Jun 06, 2024
SkinMedica® Celebrates 25 Years of Empowering Radiant Skin
PRNewswire • 8:00am
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers
PRNewswire • 8:00am
Jun 05, 2024
AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383
PRNewswire • 9:00am
Jun 04, 2024
RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
PRNewswire • 8:00am
Refer Your Friends to All?, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50
PRNewswire • 8:00am
Jun 03, 2024
Why Investors Are Eyeing AbbVie Inc (ABBV): The Key Drivers of Market Outperformance and Growth Potential
GuruFocus Research • 10:02am
AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
PRNewswire • 8:00am
May 31, 2024
AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
PRNewswire • 2:00am
May 28, 2024
AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform
PRNewswire • 8:00am
Navigating Market Uncertainty: Intrinsic Value of AbbVie Inc
GuruFocus Research • 6:00am
May 23, 2024
AbbVie Completes Acquisition of Landos Biopharma
PRNewswire • 4:00pm
May 17, 2024
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®
PRNewswire • 7:00am
May 14, 2024
Unlocking Intrinsic Value: Analysis of AbbVie Inc
GuruFocus Research • 6:00am
May 13, 2024
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
PRNewswire • 8:00am
May 06, 2024
AbbVie to Present at the Bank of America Securities Healthcare Conference
PRNewswire • 8:00am
May 04, 2024
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight
GuruFocus Research • 11:01pm
Apr 30, 2024
AbbVie Inc: An Exploration into Its Intrinsic Value
GuruFocus Research • 6:00am
Apr 27, 2024
AbbVie Inc (ABBV) Q1 2024 Earnings Call Transcript Highlights: Surpassing Expectations with Strong Growth in Key Areas
GuruFocus Research • 1:07am
Q1 2024 AbbVie Inc Earnings Call Transcript
GuruFocus Research • 12:53am
Apr 26, 2024
AbbVie Inc (ABBV) Q1 2024 Earnings: Adjusted EPS Tops Estimates Despite Revenue Challenges
GuruFocus Research • 7:11am
Apr 25, 2024
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
PRNewswire • 8:00am
Apr 23, 2024
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
PRNewswire • 8:00am
Apr 18, 2024
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
PRNewswire • 8:00am
Apr 16, 2024
Invest with Confidence: Intrinsic Value Unveiled of AbbVie Inc
GuruFocus Research • 6:00am
- 1
- 2
Show
Entries
Headlines
Total 0- 1
No recent news